Faatz, H., Feltgen, N., Gutfleisch, M., Heimes-Bussmann, B., Krohne, T. U., Liakopoulos, S., Liegl, R., Lommatzsch, A., Mussinghoff, P., Rehak, M., Schmitz-Valckenberg, S., Spital, G., Stanzel, B., Ziemssen, F., Haegele, B., Junkes, C., Porstner, M., Voegeler, J., Gmeiner, B. and Pauleikhoff, D. (2023). Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naive and previously treated patients with neovascular AMD. Ophthalmologie, 120 (3). S. 294 - 301. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7218

Full text not available from this repository.

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is the standard treatment for patients with neovascular age-related macular degeneration (nAMD). In addition to the approved substances ranibizumab (Lucentis (R), Novartis) and aflibercept (Eylea (R), Bayer), bevacizumab (Avastin (R), Roche) is also available. Furthermore, brolucizumab (Beovu (R), Novartis) has been approved and has been available in Germany since April 2020. The multicenter, noninterventional prospective BLUE SKY study investigates brolucizumab treatment with different schemes in 600 treatment-naive and pretreated nAMD patients in routine clinical practice over a 24-month period. Besides general patient data, visual acuity and treatment data will be documented. Fluorescein angiography, fundus photography, spectral domain optical coherence tomography and swept-source optical coherence tomography angiography will be performed and analyzed by reading centers. The focus of the analysis will be on the intraretinal and subretinal fluid distribution as well as morphological MNV changes and injection frequency. Also, safety and adverse drug effects of brolucizumab, with a specific focus on inflammatory complications, particularly retinal (occlusive) vasculitis will be evaluated.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Faatz, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Feltgen, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gutfleisch, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heimes-Bussmann, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krohne, T. U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liakopoulos, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liegl, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lommatzsch, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mussinghoff, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rehak, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmitz-Valckenberg, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spital, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stanzel, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ziemssen, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haegele, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Junkes, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Porstner, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Voegeler, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gmeiner, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pauleikhoff, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-690689
DOI: 10.1007/s00347-022-01731-2
Journal or Publication Title: Ophthalmologie
Volume: 120
Number: 3
Page Range: S. 294 - 301
Date: 2023
Publisher: SPRINGER HEIDELBERG
Place of Publication: HEIDELBERG
ISSN: 2731-7218
Language: German
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MACULAR DEGENERATION; VISUAL-ACUITYMultiple languages
OphthalmologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69068

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item